Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial - PubMed
3 hours ago
- #Clinical Trial
- #Breast Cancer
- #Fovinaciclib
- Fovinaciclib plus aromatase inhibitor significantly improves progression-free survival in first-line treatment of advanced hormone receptor-positive, ERBB2-negative breast cancer.
- The phase 3 trial involved 417 patients in China, with a hazard ratio of 0.55 favoring fovinaciclib, and median PFS not reached versus 20.2 months for placebo.
- Safety profile was manageable with hematologic toxicities as common adverse events, low discontinuation rates (1.4%), and no negative impact on quality of life.
- Overall survival data are immature at the time of analysis, with only 9.6% of events reported.
- The study supports fovinaciclib as an effective addition to first-line therapy, showing consistent benefits across most patient subgroups.